Evidence map›Paper›PMID 22820842›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2012

Statins inhibit pulmonary artery smooth muscle cell proliferation by upregulation of HO-1 and p21WAF1.

Manxiang Li, Yuan Liu, Hongyang Shi, Yonghong Zhang, Guizuo Wang, Jing Xu, Jiamei Lu, Dexin Zhang, Xinming Xie, Dong Han and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Are statins beneficial for the treatment of pulmonary hypertension?Chronic diseases and translational medicine · 2017
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Heme oxygenase in neonatal lung injury and repair.Antioxidants & redox signaling · 2014
    Review
  12. Article
  13. Article
  14. The role and mechanism of AMPK in pulmonary hypertension.Therapeutic advances in respiratory disease
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Manxiang LiRespiratory Diseases Research Center, The Second Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, Shaanxi, 710004, People's Republic of China. manxiangli@hotmail.com
Yuan Liu
Hongyang Shi
Yonghong Zhang
Guizuo Wang
Jing Xu
Jiamei Lu
Dexin Zhang
Xinming Xie
Dong Han
Yuanyuan Wu
Shaojun Li
Second Affiliated Hospital of Xi'an Jiaotong University · CNShaanxi Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Simvastatin is a 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor, which has been shown to ameliorate the development of pulmonary hypertension in animal model by suppression of pulmonary artery smooth muscle cells (PASMCs) proliferation, yet its underlying molecular mechanisms are not completely understood. In this study, we show that simvastatin dose-dependently inhibited serotonin-stimulated PASMCs proliferation. This was accompanied with the parallel induction of heme oxyganase-1 (HO-1) and upregulation of p21(WAF1). More importantly, we found that Tin-protoporphyrin (SnPP), a selective inhibitor of HO-1, could block the effect of simvastatin on inhibition of cell proliferation in response to serotonin and abolish simvastatin-induced p21(WAF1) expression. The inhibitive effect of simvastatin on cell proliferation was also significantly suppressed by silencing p21(WAF1) with siRNA transfection. The extent of effect of SnPP on inhibition of cell proliferation was similar to that of lack of p21(WAF1) by siRNA transfection. Taken together, our study suggests that simvastatin inhibits PASMCs proliferation by sequential upregulation of HO-1 and p21(WAF1) to benefit pulmonary hypertension.

Indexed as

AnimalsCell Culture TechniquesCell ProliferationCells, CulturedCyclin-Dependent Kinase Inhibitor p21Heme Oxygenase-1Hydroxymethylglutaryl-CoA Reductase InhibitorsHypertension, PulmonaryMyocytes, Smooth MusclePulmonary ArteryRatsRats, Sprague-DawleyRNA, Small InterferingSerotoninSimvastatinTransfectionCdkn1a protein, ratCyclin-Dependent Kinase Inhibitor p21Heme Oxygenase-1Hydroxymethylglutaryl-CoA Reductase InhibitorsRNA, Small InterferingSerotoninSimvastatin

Identifiers

PMID22820842
OpenAlexW1996104221

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.